Detail

Interferon Alfa-2a, Recombinant

Description

Name: Interferon Alfa-2a, Recombinant
Type: biotech
Groups: approved
Indication: For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
Accession Number: DB00034 ( BIOD00012, BIOD00095, BTD00012, BTD00095, DB00037)
Description: Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Roferon A Soln Inj 6 Millionliquid6000000 unitintramuscular; subcutaneous31-12-198926-08-1997Canada
Roferon A Sterile Pws 18m Unit/vialpowder for solution18000000 unitintramuscular; subcutaneous31-12-199130-09-1996Canada
Roferon A Sterile Pws 3m Unit/vialpowder for solution3000000 unitintramuscular; subcutaneous31-12-199130-09-1996Canada
Roferon A Sterile Pws 9m Unit/vialpowder for solution9000000 unitintramuscular; subcutaneous31-12-199130-09-1996Canada
Roferon-A Solution Inj. 9million I.U./0.9mlsolution9000000 unitintramuscular; subcutaneous31-12-199326-08-1997Canada
Roferon-A Sol Inj 3million Iu/vialliquid3000000 unitintramuscular; subcutaneous31-12-198925-08-1997Canada
Roferon-A Soln-liq Im Sc 4.5million I.u/mlliquid4.5 mintramuscular; subcutaneous25-04-199702-11-1999Canada
Roferon-A Soln-liq Im Sc 9million I.U./mlsolution9 mintramuscular; subcutaneous29-04-199701-11-2004Canada
Roferon-A Solution 18 Million I.U./3mlsolution18 mintramuscular; subcutaneous15-01-199714-07-2005Canada
Roferon-A Solution 3 Million I.U./mlsolution3 mintramuscular; subcutaneous25-02-199714-07-2005Canada
Roferon-A Solution 6 Million I.U./mlsolution6 mintramuscular; subcutaneous24-02-199727-07-2000Canada
Roferon-A Solution Inj 36000000unit/mlsolution36000000 unitintramuscular; subcutaneous31-12-199218-06-1997Canada

Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
Roferon A Sterile Pws 3m Unit/vialInterferon Alfa-2a, Recombinant
Roferon A Sterile Pws 18m Unit/vialInterferon Alfa-2a, Recombinant
Roferon A Sterile Pws 9m Unit/vialInterferon Alfa-2a, Recombinant
Roferon-A Solution Inj 36000000unit/mlInterferon Alfa-2a, Recombinant
Roferon-A Solution Inj. 9million I.U./0.9mlInterferon Alfa-2a, Recombinant
Roferon-A Solution 3 Million I.U./mlInterferon Alfa-2a, Recombinant
Roferon-A Soln-liq Im Sc 4.5million I.u/mlInterferon Alfa-2a, Recombinant
Roferon-A Solution 6 Million I.U./mlInterferon Alfa-2a, Recombinant
Roferon-A Soln-liq Im Sc 9million I.U./mlInterferon Alfa-2a, Recombinant
Roferon-A Solution 18 Million I.U./3mlInterferon Alfa-2a, Recombinant
Roferon A Soln Inj 6 MillionInterferon Alfa-2a, Recombinant
Roferon-A Sol Inj 3million Iu/vialInterferon Alfa-2a, Recombinant

Categories
  • No Category

Pharmacology

Indication: For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
Pharmacodynamics: Not Available
Mechanism of action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Absorption: Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.
Volume of distribution:
  • 0.223 to 0.748 L/kg [healthy people]

Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Alpha-interferons are totally filtered through the glomeruli and undergo rapid proteolytic degradation during tubular reabsorption, rendering a negligible reappearance of intact alfa interferon in the systemic circulation.
Half life: The IM half-life of interferon alfa-2a is 6 hours to 8 hours; the half-life for IV infusion is 3.7 hours to 8.5 hours (mean 5.1 hours).
Clearance: Not Available
Toxicity: Interferon alfa-2 may cause serious adverse effects such as anemia; autoimmune diseases, including vasculitis, arthritis, hemolytic anemia, and erythematosus syndrome; cardiotoxicity; hepatotoxicity; hyperthyroidism or hypothyroidism; transient ischemic attacks; leukopenia; neurotoxicity; peripheral neuropathy; and thrombocytopenia. Some lesser side effects that may not need medical attention include blurred vision, change in taste or metallic taste, cold sores or stomatitis, diarrhea, dizziness, dry mouth, dry skin or itching, flu-like syndrome, increased sweating, leg cramps, loss of appetite, nausea or vomiting, skin rash, unusual tiredness, weight loss, and partial loss of hair.
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Not Available

Packagers:
Dosage forms
FormRouteStrength
Liquidintramuscular; subcutaneous6000000 unit
Powder for solutionintramuscular; subcutaneous18000000 unit
Powder for solutionintramuscular; subcutaneous3000000 unit
Powder for solutionintramuscular; subcutaneous9000000 unit
Solutionintramuscular; subcutaneous9000000 unit
Liquidintramuscular; subcutaneous3000000 unit
Liquidintramuscular; subcutaneous4.5 m
Solutionintramuscular; subcutaneous9 m
Solutionintramuscular; subcutaneous18 m
Solutionintramuscular; subcutaneous3 m
Solutionintramuscular; subcutaneous6 m
Solutionintramuscular; subcutaneous36000000 unit

Prices
Unit descriptionCostUnit

Patents
CountryPatent NumberApprovedExpires (estimated)
2172664Canada2000-10-032016-03-26

Interactions

Drug Interactions
DrugInteraction

Food Interactions:
  • Avoid alcohol.

Taxonomy

Kingdom: Organic Compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Not Available

substituent:
  • Not Available

References

Synthesis Reference: Not Available
General Reference: Not Available
External Links:
ResourceLink
RxListhttp://www.rxlist.com/cgi/generic3/roferon.htm
Drugs.comhttp://www.drugs.com/cdi/interferon-alfa-2a-solution.html

ATC Codes:
  • Array

AHFS Codes:
  • Not Available

MSDS: Download

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
SiteLock

© Copyright 2017
The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society.
The Purple Society, a not-for-profit, section 501(c)(3) 
#273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

or

Log in with your credentials

Forgot your details?